CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling

Lysophosphatidic acid receptors stimulate a Gα12/13/RhoA-dependent gene transcription program involving the serum response factor (SRF) and its coactivator and oncogene, megakaryoblastic leukemia 1 (MKL1). Inhibitors of this pathway could serve as useful biological probes and potential cancer therapeutic agents. Through a transcription-based high-throughput serum response element-luciferase screening assay, we identified two small-molecule inhibitors of this pathway. Mechanistic studies on the more potent CCG-1423 show that it acts downstream of Rho because it blocks SRE.L-driven transcription stimulated by Gα12Q231L, Gα13Q226L, RhoA-G14V, and RhoC-G14V. The ability of CCG-1423 to block transcription activated by MKL1, but not that induced by SRF-VP16 or GAL4-VP16, suggests a mechanism targeting MKL/SRF-dependent transcriptional activation that does not involve alterations in DNA binding. Consistent with its role as a Rho/SRF pathway inhibitor, CCG-1423 displays activity in several in vitro cancer cell functional assays. CCG-1423 potently (<1 μmol/L) inhibits lysophosphatidic acid–induced DNA synthesis in PC-3 prostate cancer cells, and whereas it inhibits the growth of RhoC-overexpressing melanoma lines (A375M2 and SK-Mel-147) at nanomolar concentrations, it is less active on related lines (A375 and SK-Mel-28) that express lower levels of Rho. Similarly, CCG-1423 selectively stimulates apoptosis of the metastasis-prone, RhoC-overexpressing melanoma cell line (A375M2) compared with the parental cell line (A375). CCG-1423 inhibited Rho-dependent invasion by PC-3 prostate cancer cells, whereas it did not affect the Gαi-dependent invasion by the SKOV-3 ovarian cancer cell line. Thus, based on its profile, CCG-1423 is a promising lead compound for the development of novel pharmacologic tools to disrupt transcriptional responses of the Rho pathway in cancer. [Mol Cancer Ther 2007;6(8):2249–60]

[1]  S. Merajver,et al.  Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. , 2003, Molecular cancer therapeutics.

[2]  E. Sahai,et al.  RHO–GTPases and cancer , 2002, Nature Reviews Cancer.

[3]  C. Der,et al.  Rho GTPase-dependent transformation by G protein-coupled receptors , 2001, Oncogene.

[4]  Yi Zheng,et al.  Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S. Sprang,et al.  Structure of Giα1·GppNHp, Autoinhibition in a Gα Protein-Substrate Complex* , 1999, The Journal of Biological Chemistry.

[6]  P C Sternweis,et al.  Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by Galpha13. , 1998, Science.

[7]  Michael F. Olson,et al.  The Rho GTPase Effector ROCK Regulates Cyclin A, Cyclin D1, and p27Kip1 Levels by Distinct Mechanisms , 2006, Molecular and Cellular Biology.

[8]  J. Price,et al.  Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells , 2005, Breast Cancer Research.

[9]  T. Mak,et al.  RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. , 2005, Genes & development.

[10]  Yi Shen,et al.  Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42. , 2006, Cancer research.

[11]  J. Lacoste,et al.  Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility , 2005, Molecular and Cellular Endocrinology.

[12]  L. Brass,et al.  Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. , 2004, Molecular cancer research : MCR.

[13]  J. Gu,et al.  Breast cancer incidence in U.S. radiologic technologists , 2006, Cancer.

[14]  T. Wieland,et al.  The Guanine Nucleotide Exchange Factor p63RhoGEF, a Specific Link between Gq/11-coupled Receptor Signaling and RhoA* , 2005, Journal of Biological Chemistry.

[15]  Yan Ping Yu,et al.  Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. , 2006, Cancer research.

[16]  J. Gutkind,et al.  Regulation of G Protein-linked Guanine Nucleotide Exchange Factors for Rho, PDZ-RhoGEF, and LARG by Tyrosine Phosphorylation , 2002, The Journal of Biological Chemistry.

[17]  Eric S. Lander,et al.  Genomic analysis of metastasis reveals an essential role for RhoC , 2000, Nature.

[18]  S. Morris,et al.  Megakaryoblastic Leukemia 1, a Potent Transcriptional Coactivator for Serum Response Factor (SRF), Is Required for Serum Induction of SRF Target Genes , 2003, Molecular and Cellular Biology.

[19]  A. Gilman,et al.  p115 RhoGEF, a GTPase activating protein for Gα12 and Gα13 , 1998 .

[20]  Erik Sahai,et al.  Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis , 2003, Nature Cell Biology.

[21]  John A. Williams,et al.  CCK-A receptor activates RhoA through Gα12/13 in NIH3T3 cells , 2003 .

[22]  S. Merajver,et al.  RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. , 2000, Cancer research.

[23]  P. Mericko,et al.  Megakaryoblastic Leukemia Factor-1 Transduces Cytoskeletal Signals and Induces Smooth Muscle Cell Differentiation from Undifferentiated Embryonic Stem Cells* , 2004, Journal of Biological Chemistry.

[24]  C. Marshall,et al.  Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1 , 1998, Nature.

[25]  R. Treisman,et al.  Actin Dynamics Control SRF Activity by Regulation of Its Coactivator MAL , 2003, Cell.

[26]  A. Sharrocks,et al.  Ternary Complex Factor-Serum Response Factor Complex-Regulated Gene Activity Is Required for Cellular Proliferation and Inhibition of Apoptotic Cell Death , 2004, Molecular and Cellular Biology.

[27]  J. Iñiguez-Lluhí,et al.  A Small Conserved Surface in SUMO Is the Critical Structural Determinant of Its Transcriptional Inhibitory Properties , 2005, Molecular and Cellular Biology.

[28]  H. Mano,et al.  Gα12 activates Rho GTPase through tyrosine-phosphorylated leukemia-associated RhoGEF , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Iñiguez-Lluhí,et al.  Direct and distinguishable inhibitory roles for SUMO isoforms in the control of transcriptional synergy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Gutkind,et al.  RGS-containing RhoGEFs: the missing link between transforming G proteins and Rho? , 2001, Oncogene.

[31]  S. Merajver,et al.  RhoC Induces Differential Expression of Genes Involved in Invasion and Metastasis in MCF10A Breast Cells , 2004, Breast Cancer Research and Treatment.

[32]  F. Cuttitta,et al.  Adrenomedullin and cancer , 2003, Regulatory Peptides.

[33]  L. Pustilnik,et al.  Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. , 1999, The Journal of pharmacology and experimental therapeutics.

[34]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[35]  J. Ranger-Moore,et al.  The role of Rac1 in maintaining malignant phenotype of mouse skin tumor cells. , 2006, Cancer letters.

[36]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[37]  N. Longo,et al.  Stromal Cell-Derived Factor-1α Promotes Melanoma Cell Invasion across Basement Membranes Involving Stimulation of Membrane-Type 1 Matrix Metalloproteinase and Rho GTPase Activities , 2004, Cancer Research.

[38]  Stanley R Krystek,et al.  Chemical Genetics Reveals an RGS/G-Protein Role in the Action of a Compound , 2006, PLoS genetics.

[39]  C. V. Golen,et al.  RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility , 2006, Oncogene.

[40]  K. Tasaka,et al.  Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. , 2002, Cancer research.

[41]  N. Goto,et al.  Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma , 2003, Cancer Chemotherapy and Pharmacology.

[42]  G. Mills,et al.  The emerging role of lysophosphatidic acid in cancer , 2003, Nature Reviews Cancer.

[43]  H. Friess,et al.  Epiregulin is Up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. , 2000, Biochemical and biophysical research communications.

[44]  P. Casey,et al.  A Role for the G12 Family of Heterotrimeric G Proteins in Prostate Cancer Invasion* , 2006, Journal of Biological Chemistry.

[45]  C. Murga,et al.  G protein-coupled receptor kinase 2 negatively regulates chemokine signaling at a level downstream from G protein subunits. , 2005, Molecular biology of the cell.

[46]  M. Caligiuri,et al.  Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[47]  H. Kuwano,et al.  Correlation between RhoA overexpression and tumour progression in esophageal squamous cell carcinoma. , 2005, European Journal of Surgical Oncology.

[48]  K. Lawler,et al.  Mobility and invasiveness of metastatic esophageal cancer are potentiated by shear stress in a ROCK- and Ras-dependent manner. , 2006, American journal of physiology. Cell physiology.

[49]  S. Merajver,et al.  A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  Chen Li,et al.  Identification of a novel alternative splicing variant of RGS5 mRNA in human ocular tissues , 2005, The FEBS journal.

[51]  G. Prendergast.  Molecular cancer therapeutics : strategies for drug discovery and development , 2005 .

[52]  G. Schultz,et al.  Receptor-dependent RhoA Activation in G12/G13-deficient Cells , 2003, Journal of Biological Chemistry.

[53]  S. Virtanen,et al.  Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. , 2002, Cancer research.

[54]  R. Prywes,et al.  Expression profiling of serum inducible genes identifies a subset of SRF target genes that are MKL dependent , 2004, BMC Molecular Biology.

[55]  N. Goto,et al.  WF‐536 INHIBITS METASTATIC INVASION BY ENHANCING THE HOST CELL BARRIER and INHIBITING TUMOUR CELL MOTILITY , 2003, Clinical and experimental pharmacology & physiology.

[56]  Shuang Huang,et al.  Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway , 2004, Cancer Research.

[57]  Saroj P. Mathupala,et al.  Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria , 2006, Oncogene.

[58]  G. Bollag,et al.  Identification of a Novel Guanine Nucleotide Exchange Factor for the Rho GTPase* , 1996, The Journal of Biological Chemistry.

[59]  R. Schwartz,et al.  Cardiac Tissue Enriched Factors Serum Response Factor and GATA-4 Are Mutual Coregulators , 2000, Molecular and Cellular Biology.

[60]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[61]  Min Liu,et al.  Thrombin and Lysophosphatidic Acid Receptors Utilize Distinct rhoGEFs in Prostate Cancer Cells* , 2004, Journal of Biological Chemistry.

[62]  J. Iñiguez-Lluhí,et al.  A Synergy Control Motif within the Attenuator Domain of CCAAT/Enhancer-binding Protein α Inhibits Transcriptional Synergy through Its PIASy-enhanced Modification by SUMO-1 or SUMO-3* , 2003, The Journal of Biological Chemistry.

[63]  T. Sawyer.  Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors , 2004, Expert opinion on investigational drugs.

[64]  W. Gerald,et al.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.

[65]  N. Kuzumaki,et al.  Transcriptional activity of megakaryoblastic leukemia 1 (MKL1) is repressed by SUMO modification , 2005, Genes to cells : devoted to molecular & cellular mechanisms.